Rodney A. Hayward, MD; Harlan M. Krumholz, MD; Donna M. Zulman, MD; Justin W. Timbie, PhD; Sandeep Vijan, MD, MSc
Although treating to lipid targets (â€œtreat to targetâ€) is widely recommended for coronary artery disease (CAD) prevention, some have advocated administering fixed doses of statins based on a person's estimated net benefit (â€œtailored treatmentâ€).
To examine how a tailored treatment approach to statin therapy compares with a treat-to-target approach.
Simulated model of population-level effects of treat-to-target and tailored treatment approaches to statin therapy.
Statin trials from 1994 to 2009 and nationally representative CAD risk factor data.
U.S. persons aged 30 to 75 years with no history of myocardial infarction.
Lifetime effects of 5 years of treatment.
Societal and patient.
Tailored treatment based on a person's 5-year CAD risk (simvastatin, 40 mg, for 5% to 15% CAD risk and atorvastatin, 40 mg, for CAD risk >15%) versus treat-to-target approaches that escalate statin dose per National Cholesterol Education Program [NCEP] III guidelines (including an intensive approach that advances treatment whenever intensification is optional by NCEP III criteria).
Quality-adjusted life-years (QALYs).
Compared with the standard NCEP III approach, the intensive NCEP III approach treated 15 million more persons and saved 570Â 000 more QALYs over 5 years. The tailored strategy treated a similar number of persons, as did the intensive NCEP III approach, but saved 500Â 000 more QALYs and treated fewer persons with high-dose statins.
No circumstances were found in which a treat-to-target approach was preferable to tailored treatment.
Model assumptions were based on available clinical data, which included few persons 75 years or older.
A tailored treatment strategy prevents more CAD events while treating fewer persons with high-dose statins than low-density lipoprotein cholesterolâ€“based target approaches. Results were robust, even with assumptions favoring a treat-to-target approach.
Department of Veteran Affairs Health Services Research & Development Service's Quality Enhancement Research Initiative.
Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease. Ann Intern Med. ;152:69–77. doi: 10.7326/0003-4819-152-2-201001190-00004
Download citation file:
Published: Ann Intern Med. 2010;152(2):69-77.
Cardiology, Coronary Risk Factors, Dyslipidemia, Prevention/Screening.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use